The 2021 swine flu pandemic viruses were novel H1N1 vaccines designed to protect against the new pandemic H1N1 strain. These new pandemic viruses were engineered from a strain of virus that had never before been studied or identified. Since there has never been a strain of H1N1 that caused an epidemic, there is no record of previous natural infections with H1N1. Since this is the first time this has happened, there is still a lot of research and testing going on to determine the safety and effectiveness of these new H1N1 vaccines. This H1N1 vaccine will be the first of its kind and is still being developed.
Unlike the regular seasonal flu vaccines, which are produced in a lab and only after the appropriate tests are conducted, the new swine flu vaccines are made in the same office that does the regular seasonal flu shots. Both the regular seasonal flu vaccines and the new one are made of a live virus. Therefore, it poses little or no risk to those who have a weaker immune system. However, there are those people who have immune system deficiencies that still might be affected by the new H1N1 vaccines. This includes people whose immune systems have been severely compromised by medical conditions such as HIV/AIDS or cancer treatment.
One of the most promising methods currently being used in the fight against this type of illness is the use of two doses. With this method, the immune response to the vaccine is altered so that the immune system will no longer respond to the first vaccine. The second dose is given at a later time, usually one month or so after the first dose. Of course, it is important to remember that even when the immune response has been reduced, there will still be an individual who experiences the full effects of the H1N1 flu. However, with the use of two doses, this reduces the risk of an unresponded case of H1N1 flu, which means there should be less cases of this type of illness in the future.
No comments:
Post a Comment